Stanford University has recently published an update of the list of the top 2% most widely cited scientists in different disciplines, the World’s Top 2% Scientists. This ranking, considered the most…
Read More
Chemotargets representatives took a “worldwide tour” during September and October 2022, to showcase Chemotargets products and services at different conferences and meetings. In Montréal, Canada, our CSO Jordi Mestres participated…
Chemotargets will contribute to the development of the repurposing platform for the REMEDi4ALL project, using its technology platforms: ProSurfScan, for AI-based drug design; CLARITY, for efficacy and safety prediction of…
This summer, Chemotargets was presenting CLARITYpv at several international audience conferences: 30th June – 2nd July – Japan Society of Toxicology, Tokushima (Japan) https://www.jsot2022.jp/ Conference link Conference link
A formal collaboration to advance a common internal pipeline of drug development projects Barcelona, 16 March 2022 – Today we announce the start of the formal collaboration between Acellera and…
CloudScientific as the local distributor in China of Chemotargets’ CLARITY and CLARITY PV technology platforms Shanghai, China and Barcelona, Spain – January 17th, 2022. Chemotargets is proud to appoint CloudScientific as the local…
Drug discovery biotech firm Chemotargets and the Centre for Genomic Regulation (CRG) have signed a strategic agreement to accelerate the development of new targeted therapies that respond to unmet clinical…
This week Chemotargets announces the launch of CLARITY PV, a new product for translational safety and pharmacovigilance professionals. Barcelona, July 5th, 2021. Chemotargets launches CLARITY PV, a new web-based platform…
The Innovative SME Seal, valid for three years, recognizes the high level of innovation in the projects, products and services of Chemotargets. Barcelona, June 1st, 2021. Chemotargets has been awarded…
In less than 12 months, the collaboration between Chemotargets and Galyan Bio yields a scaffold for first-in-class clinical candidates in difficult area of neurodegenerative disease. Chemotargets employed its proprietary AI-driven…
